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The identification of myriocin-binding proteins 
James K Chen , I* William S Lane* and Stuart L Schreiberl 
Background: Myriocin is a natural product that potently induces apoptosis of a 
murine cytotoxic T lymphocyte cell line (CTLL-2) and inhibits a serine 
palmitoyltransferase (SPT) activity that has been detected in cell extracts and is 
thought to initiate sphingolipid biosynthesis. Because SPT has never been 
biochemically purified and a comprehensive appraisal of myriocin-binding 
proteins has not been conducted, we isolated specific targets using myriocin- 
based affinity chromatography. 
Results: Myriocin derivatives were synthesized and evaluated using CTLL-2 
proliferation and SPT activity assays. Guided by these results, affinity 
chromatography matrices were prepared and two specific myriocin-binding 
proteins were isolated from CTLL-2 lysates. Analyses of these polypeptides 
establish conclusively that they are murine LCBl and LCBP, mammalian 
homologs of two yeast proteins that have been genetically linked to 
sphingolipid biosynthesis. 
Conclusions: The ability of myriocin-containing matrices to bind factors that 
have SPT activity and the exclusive isolation of LCBl and LCB2 as myriocin- 
binding proteins demonstrates that the two proteins are directly responsible for 
SPT activity and that myriocin acts directly upon these polypeptides. 
Introduction 
Myriocin (1; Figure l), also known as thermozymocidin 
and ISP-1, is a sphingosine-like natural product, initially 
characterized as an antifungal metabolite of the rhermo- 
philic molds M~ceLia sterilia and M~~~?ococc~m aLbomye.s [ 1,2]. 
Screening programs for immunosuppressants have recently 
re-isolated myriocin from /J-ark sinclairii, a fungus tradi- 
tionally used in Chinese medicine for eternal youth [3]. 
The natural product potently inhibits lymphocyte prolif- 
eration in mouse allogenic mixed lymphocyte reactions 
(MLRs), T cell-dependent antibody production, and the 
generation of alloreactive cytotoxic T lymphocytes. In 
these in vitro and in u&o assays, myriocin is equipotent to 
FK506 and approximately lO- to lOO-fold more potent 
than cyclosporin A, two clinically prescribed immunosup- 
pressants. The possible therapeutic efficacy of m)-riocin 
has sparked a renewed interest in this natural product, 
prompting a resurgence in synthetic and biological investi- 
gations of myriocin and its analogs. Furthermore, re-analy- 
sis of M. sterilia fermentation broths has yielded additional 
immunosuppressive metabolites called mycestericins, which 
are structurally related to myriocin [&6]. 
Elucidating the biological mechanism of myriocin has there- 
fore been an area of active research. Initial studies have 
demonstrated that myriocin is mechanistically distinct from 
FKS06 and cyclosporin A. It does not block interleukin 2 
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(IL-Z) production by antigen- or mitogen-stimulated T cells. 
but potently inhibits the proliferation of CTLL-2 cells, a 
murine cytotoxic T lymphocyte line that is IL-2 dependent 
[3]. Although this observation initially prompted specula- 
tion that myriocin might specifically abrogate IL-2 recep- 
tor-mediated signaling, subsequent studies by Nakamura et 
aL [7] and our laboratory (data not shown) indicate other- 
wise. Many transformed ccl1 lines, including several other 
IL-2 dependent cell types, are not affected by myriocin, 
suggesting that myriocin is merely specific for certain lym- 
phocyte lineages. Structural similarities between myriocin 
and sphingosine-derived molecules also suggest that myri- 
ocin might perturb sphingolipid biosynthetic or signaling 
pathways, and experimental support for this hypothesis has 
been obtained by two independent laboratories. Riezman 
and coworkers [8] reported that myriocin abrogates ceramide 
synthesis in Saccharoq~ces mwisiae and ultimately causes 
cell death. A more precise mechanism for this general effect 
on ceramide production was then determined by Miyake 
et al. [9], who established that myriocin inhibits a serine 
palmitoyltransferase (SPT) activity that can be detected in 
CTLL-Z-derived microsomes with an inhibition constant 
of 280 PM. 
SPT is a membrane-associated activity that catalyzes the 
formation of 3-ketodihydrosphingosine from serine and pal- 
mitoyl CoA in a pyridoxal 5’-phosphate (PLPJ-dependent 
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Effects of myriocin (l), FTY720 (2) and sphingofungin B (3) on serine 
palmitoyltransferase (SPT) activity. The numbering system for the 
carbon skeleton of myriocin is shown. 
manner (Figure 1) [lo-141. Because SPT is the rate-limit- 
ing step in sphingolipid biosynthesis (Figure 2) and sphin- 
golipid metabolites are important mediators of cellular 
proliferation and programmed cell death, it is conceivable 
that myriocin-induced perturbations might degrade the 
cellular immune response. In agreement with this hypo- 
thesis, micromolar concentrations of dihydrosphingosine, 
sphingosine or sphingosine l-phosphate - downstream 
metabolites in the biosynthetic pathway -are able to sup- 
press the effects of myriocin on CTLL-2 cells [9]. Sphingo- 
myelinase and CZ-ceramide also effect partial restoration 
of cell proliferation. Of these compounds, sphingosine l- 
phosphate rescues the cells most effectively, and more 
recent studies have extended these findings, revealing that 
myriocin actually induces CTLL-2 programmed cell death 
and that high levels of exogenous sphingosine can also 
cause apoptosis [7]. Despite these provocative observa- 
tions, a direct connection between SPT inhibition and 
immunosuppression remains to be demonstrated. The 
ability of sphingosine and sphingosine l-phosphate to 
protect CTLL-2 cells from myriocin-induced apoptosis 
does not necessarily indicate that intracellular sphingo- 
lipid depletion is the cause of programmed cell death. Pre- 
vious studies clearly show that sphingosine l-phosphate 
can generally suppress apoptosis induced by a variety of 
stressors, and sphingosine is known to be phosphorylated 
rapidly upon introduction to cells [ 1.5-171. Furthermore, 
exogenous CZceramide can prevent CTLL-2 apoptosis 
triggered by IL-2 deprivation by inducing G, arrest and 
inhibiting b&X,, degradation [ 181. 
These mechanistic ambiguities are exacerbated by the bio- 
logical properties of myriocin-related compounds. Struc- 
tural analogs such as Z-alkyl-Z-amino-1,3-propanediols, 
FTY720 (2; Figure 1) and Z-substituted-Z-aminoethanols 
are equipotent to myriocin in MLR and skin-allograft 
assays but do not inhibit SPT [19,20]. Moreover, a myri- 
ocin-like SPT inhibitor, sphingofungin B (3; Figure l), 
is sensitive to structural modifications that are known to 
be inconsequential to the immunosuppressive activity of 
myriocin. suggesting an SPT-independent mechanism for 
immune response regulation [Zl]. Fujita and coworkers 
[19] have speculated that these synthetic derivatives 
inhibit downstream sphingolipid biosynthesis enzymes 
such as dihydrosphingosine ;V-acyltransferase, but addi- 
tional studies suggest otherwise. ,Molecules that are struc- 
turally related to the immunosuppressive Zsubstituted- 
Z-amino-1,3-propanediols or Z-substituted-Z-aminoethanols 
do not inhibit the incorporation of serine into sphingo- 
lipids [22.23], and fumonisin Bl, a potent inhibitor of 
dihydrosphingosine :V-acyltransferase. does not prevent 
the rescue of myriocin-treated CTLL-2 cells by exogenous 
sphingosine [9]. These experimental observations argue 
for two possible scenarios: that myriocin suppresses the 
immune system by inhibiting SPT in lymphocytes and 
the myriocin analogs fortuitously target another protein 
that is necessary for the immune response; or that myri- 
ocin itself has two biochemical targets, one related to SPT 
activity and the other essential for normal immunological 
activity - and myriocin analogs retain this second activity 
at the expense of SPT inhibition. 
Despite these questions, a systematic appraisal of myri- 
ocin-binding proteins has not been accomplished. In prin- 
ciple, such polypeptides could be components of SPT, 
which has eluded biochemical purification since its discov- 
ery in 1967 [lo]. Complementation studies of 5’. mzzisiae 
auxotrophs have identified two genes that encode putative 
SPT subunits, L.CBZ and LCBZ [24-261, and mammalian 
homologs have recently been cloned (Figure 3) [27,28]. 
.4lthough overexpression studies suggest indirectly that 
both yeast proteins are essential for SPT activity, similar 
analyses of the mammalian SPT proteins are contradictov 
and inconclusive [X-28]. Weiss and Stoffel [27] have 
reported that coexpression of murine LCBl and LCBZ or 
overexpression of LCBZ alone in HEK 293 cells causes a 
threefold increase in SPT activity compared with untrans- 
fected cells, yet HEK 293 cells transfected with only LCBl 
cDN.4 are unchanged. Furthermore, overexpression of an 
inactive LCBZ mutant abolishes SPT activity in HEK 293 
cells. These results support a role for mammalian LCB? in 
3-ketodihydrosphingosine synthesis but leave the func- 
tional relevance of LCBl in question. In contrast, Hanada 
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Figure 2 
The current model of mammalian sphingolipid 
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et ol. [ZS] have demonstrated that SPB-1 Chinese hamster 
ovary (CHO) cells, a cell line that contains thermolabile 
SPT, can regain 3-ketodihydrosphingosine synthesis at non- 
permissive temperatures upon transfection with hamster 
LCBl cDNA. The participation of LCBl in mammalian 
sphingolipid biosynthesis is also substantiated by the 
ability of NiZ+-’ Immobilized resins to partially sequester 
microsomal SPT activity from SPB-1 CHO cells overex- 
pressing His,-tagged hamster LCBl protein. The discrep- 
ancies between these two studies remain to be resolved, 
and confirmation of these proteins or other polypeptides 
as SPT subunits awaits the purification of this elusive 
enzymatic activity. It is also possible that myriocin targets 
other cellular proteins that could be direct mediators of 
the cellular immune response. This scenario is reasonable 
because sphingosine-derived molecules often have pleio- 
tropic biological effects. For example, sphingosine l-phos- 
phate has distinct extracellular and intracellular targets 
that independently mediate its effects on cell adhesion 
and cell proliferation [17,29]. 
To address these issues, we have initiated biochemical 
studies towards the isolation and characterization of myri- 
ocin-binding proteins. Myriocin was obtained from fer- 
mentation broths of M. sterilia, and previously unknown 
synthetic derivatives of this natural product were prepared 
and evaluated in CTIA.2 proliferation and microsomal 
SP’lY assays. Guided by these results, myriocin-containing 
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Schematic representation of the yeast and mammalian LCB proteins. 
Putative transmembrane (TM) and PLP-binding regions (PLP) are shown. 
affinity matrices were then developed, yielding two spe- 
cific binding proteins from CTLL-2 microsomes. Molecu- 
lar analyses of these polypeptides using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
LCBl- and LCBZ-specific antibodies, and mass spectrome- 
try (MS)-based sequencing conclusively establish that the 
two proteins are murine LCBl and LCBZ. The implica- 
tions and limitations of these observations will be discussed. 
Results and discussion 
Chemical synthesis of myriocin derivatives 
Aliphatic linkers of suitable length and amide-forming 
transformations have traditionally been used in the prepa- 
ration of affinity chromatography reagents. The unique 
chemical and structural properties of myriocin, however, 
argue against these conventional strategies. hlyriocin is 
highly insoluble in most aqueous or organic solvents; its 
tail group is very hydrophobic, and its polar head group is 
densely functionalized. As a result, derivatizing myriocin 
with an aliphatic chain is likely to yield a ceramide-like 
compound that is highly intractable to in a&o and in vie~o 
studies, and acylation reactions might not exhibit suffi- 
cient site-selectivity. Such a dialkyl derivative would also 
be expected to exhibit significant nonspecific binding to 
cellular proteins, especially when conjugated to a solid 
support. To circumvent these possible problems, three 
myriocin-derived compounds were assessed, each contain- 
ing a pentaethylene glycol linker terminated with a latent 
thiol functionality. 
The first of these compounds is CZO-linker myriocin (4; 
Figure 4), which bears its pentaethylene glycol linker at the 
aliphatic extremity of myriocin. The myriocin portion of 
this molecular probe deviates from the natural-product 
structure in two respects: the Cl4 ketone is removed and 
the olefin geometry is altered. Incorporated for synthetic 
simplicity, these structural modifications should have no 
deleterious effects on biological activity; the E and 2 
isomers of C14-deoxomyriocin are equipotent to myriocin 
&.P+ SW 15 
(x) I 
t 
Chemistry & Blologj 
Synthesis of S-benzyl, C20-linker myriocin. (i) BzCI, pyr, rt, 74%; (ii) O,, 
Mess, CH,CI,/MeOH, -76”C, 71 o/o; (iii) NaH, TBDMSCI, THF, rt, 49%; 
(iv) MsCI, CH,CI,, 0°C then KSAc, Et,O, rt, 93%; (VI KOH(aq), 
THF/MeOH, rt, 76%; (vi) TBAF, THF, rt, 94%; (vii) Is, PhsP, imid, 
CH,CN/Et,O, rt, 96%; (viii) Ph,P, CH,CN, reflux, 99%; (ix) NaN(TMS),, 
THF, -78’C to 0 “C, 21%; (x) LiOH(aq), EtOH, 4O”C, 56%. 
in murine allogenic MLR assays [30,31]. To synthesize this 
derivative, myriocin was treated with benzoyl chloride to 
provide the fully protected lactone (5) and then reductively 
ozonized to generate the labile aldehyde (6). A Wittig cou- 
pling between the myriocin-derived aldehyde 6 and the 
ylide obtained from phosphonium iodide 14 then com- 
pleted the CZO-linker myriocin framework, albeit in poor 
yields. As would be predicted from general c&/tram selec- 
tivities of nonstabilized ylides, nuclear magnetic resonance 
(NMR) spectra of the Wittig product (15) indicate that only 
the 2 isomer is formed. Benzoyl deprotection and lactone 
hydrolysis of 15 was finally achieved by LiOH-mediated 
saponification, yielding the desired myriocin deriv-ative 4. 
Myriocin-based probes that contain modifications of the 
polar head group were also synthesized for biological eval- 
uation (Figures 5.6). $-linker myriocin (16) was prepared 
by alkylating the myriocin lactone (17) with a pentaethy- 
lene glycol derivative (19). Saponification of the modified 
lactone (20) with LiOH then generated the appropriate 
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Synthesis of S-benzyl, N-linker myriocin. (i) SOCI,, MeOH, -78°C to 
rt, 81%; (ii) BnSH, Cs,CO,, EtOH/THF, rt, 22%; (iii) DIPEA, iPrOH, 
8O”C, 38%; (iv) LiOH (aq), THF/MeOH, rt, 61%. 
myriocin derivative 16, which is functionalized at its amino 
terminus but contains a basic sp”-hybridized nitrogen 
atom. This structural moiety was intentionally retained 
because :V-acetylation of myriocin is known to signifi- 
cantly attenuate its immunosuppressive activity [30]. Design 
of the third and final myriocin-derived probe. Cl-linker 
myriocin (21) was also guided by structure-activity rela- 
tionship (SAR) data reported by Fujita et nl. [30]. Con- 
struction of this myriocin derivative required the trimethyl 
aluminum-mediated aminolysis of the N-trifluoracetyl 
myriocin lactone (26) with an amine-functionalized linker 
(ZS), forming the Wacylated myriocin derivative (27). 
Removal of the trifluoroacetyl group with potassium car- 
bonate afforded the final product 21, which is stable in 
neutral or acidic conditions but prone to relactonization 
upon prolonged exposure to base. 
Biological evaluation of myriocin derivatives 
Because Mikyake et al. [9] have established CTLL-2 cell 
proliferation as a model system for investigating myriocin 
activity, we evaluated the effects of 1, 4, 16 and 21 on this 
cell line. Consistent with previous reports 191, myriocin (1) 
inhibits CTLL-2 cell growth with an IC,, of approxi- 
mately 10 r&l, through the induction of apoptotic path- 
ways (Figure 7). The N-linker (16) and Cl-linker (21) 
compounds demonstrate significant but diminished activ- 
ity with IC,, values of approximately 500 and 300 nM. 
respectively. In contrast, the CZO-linker myriocin (4) cannot 
Figure 8 
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Synthesis of S-benzyl, Cl -linker myriocin. (i) NaN,, DMF, rt, 49%; (ii) 
BnSH, Cs,CO,, EtOH/THF, rt, 68%; (iii) NaOH(aq), Ph,P, THF, rt, 
97%; (iv) TFAA, CH,Cl,, r-t, 1009/o; fv) AIMe,, PhCH,/CH,CI,. rt, 
26%; (vi) K&O,, MeOHIH,O, rt, 72%. 
prevent CTLL-2 proliferation at concentrations up to 
5 @I. To confirm further that the iv- and Cl-linker com- 
pounds (16 and 21) are functionally equivalent to myri- 
ocin, both derivatives were then assayed for their ability to 
inhibit SPT activity in CTLL-Z-derived microsomes 
(Figure 8). hlyriocin potently inhibits this process with an 
IC,, of 0.28 r&l, and both .V- and Cl-linker myriocin have 
IC,, values of -200 nM. CZO-linker myriocin (4) has no 
significant effect on SPT activ-it);, even at micromolar con- 
centrations. These results correlate with the antiprolifera- 
tive activities of myriocin and its derivatives and indicate 
that the pentaethylene glycol-modified compounds are 
suitable probes for myriocin-binding proteins. It is noted, 
however, that X- and Cl-modifications of myriocin attenu- 
ate its ability to abrogate SPT activity more substantially 
than they affect its ability to induce CTLL-2 apoptosis. 
This effect might reflect differences in the biophysical 
properties of myriocin and its derivatives (such as mem- 
brane permeability) or the existence of multiple myriocin 
targets in CTLL-2 cells. 
Synthesis of myriocin affinity matrices 
The preparation of affinity matrices containing the N- and 
Cl-linker derivatives was then carried out using cross-linked 
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Inhibition of CTLL-2 cell growth by 
(a) myriocin and its derivatives, (b) C-20 linker 
myriocin 4, (c) N-linker myriocin 16 and 
(d) Cl -linker myriocin 21. 
agarose resins. Our original plan was to liberate the thiol 
groups in 16 and 21 by metal-ammonia reduction of the 
benzyl groups. Unfortunately, both sodium- and calcium- 
mediated deprotections resulted in complex mixtures, 
and new thiol protecting groups had to be used. The 
N-linker myriocin compound was therefore redesigned as 
the S-acetyl lactone (28), using chemical transformations 
analogous to those used in the synthesis of 20 (Figure 9). 
LiOH saponification of 28 then provided the N-linker 
myriocin thiol (a), which was reacted with ten equiva- 
lents of maleimide-functionalized Affigel 102 (30). Remain- 
ing thiol-reactive groups in the matrix were quenched 
with an excess of P-mercaptoethanol. Likewise, prepara- 
tion of the Cl-linker myriocin affinity matrix required the 
development of new carboxyl-functionalized myriocin 
derivatives. Because of the base sensitivity of Cl-linker 
myriocin, its thiol group was introduced as a trityi thio- 
ether for subsequent deprotection by trifluoroacetic acid 
and triethylsilane. The Cl4 carbonyl of myriocin WdS also 
reduced to the secondary alcohol with sodium borohy- 
dride prior to unmasking the thiol because trityl deprotec- 
tion in the presence of the ketone yields an macrocyclic 
hemiketal that is unreactive with the resin-bound male- 
imide (data not shown). This structural modification should 
not affect the ability of Cl-linker myriocin-containing 
matrices to sequester binding proteins, because myriocin 
and C14-hydroxy myriocin are equipotent in MLR assays 
[30]. Maleimide-functionalized agarose (30) was therefore 
reacted with the Cl-linker myriocin thiol and P-mercap- 
toethanol to provide the second myriocin affinity matrix 
(32; Figure lo), using conditions identical to those for the 
synthesis of 31. 
LJltimately, the efficacy of these myriocin affinity matrices 
depends upon their capacity for specific protein binding 
from cell Iysates. To evaluate the macromolecular accessi- 
bility of matrices 31 and 32. their ability to sequester SPT 
activity was examined (see Figure 10). The N-linker (31) 
and Cl-linker (32) myriocin matrices were incubated with 
detergent-solubilized CTLL-2 microsomes and the resul- 
tant supernatant was assayed for SPT activity. These exper- 
iments clearly demonstrate that the AT-linker myriocin affin- 
ity matrix can deplete cell lysates of the enzymatic activity, 
Figure 8 
Inhibition of CTLL-2 microsomal serine palmitoyltransferase activity by 
myriocin (1, black circles), C20-linker myriocin (4, red triangles), 
N-linker myriocin (16, blue squares), and Cl -linker myriocin (21, green 
diamonds). 
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Synthesis of N-linker myriocin affinity matrix. (i) LiOH(aq), THF/MeOH, 
O”C, 60%; (ii) TCEP, MeOH/PBS (pH 7.4), rt, 100%. 
Figure 10 
whereas a P-mercaptoethanol-derivatized control matrix 
(33) does not affect soluble SPT levels. Surprisingly, the 
Cl-linker myriocin matrix has significantly diminished 
capacity for binding the activity. presumably due to sub- 
optimal ligand presentation on the agarose support. This 
hypothesis is substantiated by the ability of both myriocin 
derivatives to deplete SPT activity from cell lysates when 
they are conjugated to polydimethylacrylamide beads (data 
not shown). Guided by these observations, the N-linker 
myriocin matrix (31) was selected for further studies in 
conjunction with CTLL-2 lysates. 
Isolation and characterization of myriocin-binding proteins 
in CTLL-2 cells 
Subcellular fractions of CTLL-2 lysates were analyzed 
with the IV-linker myriocin matrix (31) on an individual 
basis to identify specific myriocin-binding polypeptides. 
Differential centrifugation and partial detergent solubiliza- 
tion provided four separate fractions: proteins associated 
with intact nuclei, mitochondria and lysosomes; microso- 
ma1 proteins not solubilized by 0.1% IGEPAL CA 630; 
microsomal proteins solubilized by 0.1% IGEPAL CA 630; 
and cytosolic proteins. Each subcellular fraction was incu- 
bated with 31 (final apparent concentration = 8.1 @I) in 
the presence or absence of soluble myriocin (final concen- 
tration = 4.0 @I), and, after extensive washing, sequestered 
proteins were denatured from the myriocin-containing beads 
Binding of factors comprising serine 
palmitoyltransferase activity by myriocin- 
containing matrices. 
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Detergent-solubilized proteins from CTLL-2 microsomes that bind to 
the /V-linker myriocin matrix (31). (a) Complete range of matrix- 
associated proteins. (b) Close-up view of the 50-60 kDa region. 
Specific myriocin-binding proteins p51 and p55 do not associate with 
the affinity matrix in the presence of soluble myriocin. (The 60 kDa 
protein in this gel that appears to be able to compete with myriocin is 
nonreproducible and was not characterized further). 
and separated by SDS-PAGE. Specific myriocin-binding 
proteins were then identified by the ability of soluble 
myriocin to abrogate their interactions with the natural- 
product-displaying affinity matrix. 
Regardless of the cellular fraction, the vast majority of 
matrix-associated proteins are nonspecific in nature, consis- 
tent with the hydrophobic character of this natural product. 
Two polypeptides, however, are specific myriocin-binding 
proteins with apparent molecular weights of 51 and 5S kDa 
(Figure 11). These proteins, ~51 and ~5.5, are predom- 
inantly associated with the IGEPAL-CA-630-solubilized 
microsomal fraction, although they also segregate with cyto- 
solic proteins to some degree. This pattern of subcellular 
localization is reminiscent of previous reports that SPT 
Figure 12 
activity resides in the endoplasmic reticulum and can be 
membrane-dissociated with nonionic detergents [27,32]. 
SPT activities in CTLL-2 subcellular fractions were there- 
fore measured 171 d-o, substantiating this correlation: the 
highest levels of SPT activity were found in the IGEPAL- 
C,4-630-solubilized CTLL-2 microsomes and some residual 
activity was associated with the cytosol (Figure 12). Given 
this empirical correspondence and the apparent masses of 
the myriocin-binding proteins, it seemed likely that the two 
polypeptides are identical to murine LCBl and LCB2. 
Although the apparent molecular weights of pS1 and pS5 
do not exactly match those calculated for LCBl (53 kDa) 
and LCBZ (63 kDa), transcription and translation of LCBl 
and LCB2 cDXAs i?z wtru yield products that co-migrate 
with the two isolated proteins in SDS-PAGE (data not 
shown). These in &w-translated products should be iden- 
tical to the endogenous CTLL-2 LCB proteins because 
previous studies demonstrate that the two putative SPT 
subunits do not undergo post-translational modifications 
[27]. Further characterization of pS1 and pS5 was subse- 
quently conducted though sequencing by ion-trap mass 
spectrometry (?vfS). Individual protein bands were excised 
from SDS-PAGE gels and proteolyically digested in gel 
with trypsin. The resultant peptides were then fraction- 
ated by reverse-phase microcapillary high performance 
liquid chromatography (HPLC) and subjected to MS frag- 
mentation and analysis, producing spectra for sequence 
interpretation and database correlation [33,33]. The iso- 
lated pS1 protein yielded a peptide fragment correspond- 
ing to murine LCBl (VC’V’WEQTEEELQR, residues 
446itS9) along with a few peptides from isobaric proteins, 
and the p.5.5 protein afforded several fragments of LCBZ 
(SSTATVAAt\GQIHH\‘TENGGLYK, residues 32-M: 
HNNMQSLEK? residues 280-288: IVIGVVWGFPAT- 
PIIESR, residues -MS-SOS; EIDEVGDLLQLK, residues 
525-536: and LVPLLDRPFI~ETTYEETED. residues 
512-560). These results indicate that the SDS-PAGE 
Subcellular localization of serine 
palmitoyltransferase activity (SPT). (a) SPT 
activity in various lysate fractions obtained by 
differential centrifugation. (b) Solubilization of 
microsomal SPT activity by IGEPAL CA 630. 
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bands corresponding to ~51 and ~5.5 contain the putative 
SPT subunits and therefore LCBl and LCBZ associate 
with the LV-linker myriocin matrix (31). Due to the non- 
quantitative character of MS and the abundance of non- 
specific binding proteins, it is difficult to ascertain from 
these data alone whether LCBl and LCBZ are the primary 
constituents of the p.51 and p.5.5 bands, respectively. The 
relative scarcity of LCBl-derived peptides could be due 
to inherent chemical properties of LCBl that impede its 
proteolysis or mass spectrometry analysis. 
Final confirmation that ~51 is murine LCBl and ~55 is 
murine LCBZ was obtained by western-blot analyses of 
matrix-associated proteins (Figure 13). Specific polyclonal 
antibodies were generated against unique carboxy-terminal 
regions of LCBl (STGSREKDVKLLQ.41, residues 401- 
415) and LCB2 (KYSRHRLVPLLDRPF, residues 53& 
S50) and used to probe affinity-matrix-bound proteins that 
were separated by SDS-PAGE and transferred to a PDVF 
membrane. The a-LCBl antibody clearly recognizes a 
51 kDa protein that binds 31 in the absence but not pres- 
ence of soluble myriocin. Similarly, the (x-LCBZ antibody 
recognizes a 55 kDa protein that specifically associates with 
31. Neither protein could be detected with preimmune 
sera, verifying the selective nature of the antibody-protein 
interactions. In conjunction with the co-migration and MS- 
based sequencing experiments, these tests conclusively 
demonstrate that LCBl and LCBZ are specific ml;riocin- 
binding proteins in CTLL-2 microsomes. 
Biological implications and experimental limitations 
The identification of LCBl and LCBZ as myriocin-binding 
proteins corroborates previous observations that myriocin 
inhibits sphingolipid biosynthesis [8.9], and constitutes the 
first demonstration that myriocin acts directly on SPT- 
related proteins. Most importantly, it provides a biochemi- 
cal link between SPT activity and the two subunits, which 
were originally identified as putative SPT subunits in yeast 
genetic screens. The potent myriocin-mediated inhibition 
of SPT in vitro, the ability of myriocin-containing beads to 
deplete SPT activity from CTLL-2 lysates, and the specific 
isolation of endogenous LCB 1 and LCBZ by these matrices 
testifies that both LCB proteins are integral components 
of mammalian SPT, contrary to previous suppositions [27]. 
The exclusive observation of LCBl and LCB3 as specific 
myriocin-binding proteins shows for the first time that the 
two subunits are directly responsible for SPT activity and 
are not merely upstream regulators of 3-ketodihydrosphin- 
gosine biosynthesis, Xagiec et al. [26] have noted that 
LCBl- and LCBZ-related proteins such as Z-amino-3-keto- 
butyrate CoA ligase, S-amino-7-oxononanoate synthase, 
and S-aminolevulinic acid synthase are pyridoxal S’-phos- 
phate (PLP)-using homodimeric enzymes that catalyze the 
a-carbon acylation of various amino acids. It therefore seems 
likely that LCBl and LCBZ heterodimerize to maintain 
and regulate SPT activity. Alternatively, the LCB proteins 
Figure 13 
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Western blot analyses of affinity matrix-associated proteins, (a) Recog- 
nition of specific myriocin-binding protein p51 by an a-LCBI antibody. 
Cross-reactive proteins bind to the matrix nonspecifically and are also 
recognized by preimmune sera (data not shown). (b) Recognition of 
specific myriocin-binding protein p55 by an a-LCB2 antibody. Neither 
p51 or p55 is recognized by preimmune sera. 
could contribute independently to SPT activity by homod- 
imerization, but the absence of a complete PLP-binding 
site in LCBl argues against this model. In any case, the 
existence of other catalytic or regulatory SPT components 
cannot be ruled out even though none was observed in 
these experiments; myriocin might abrogate 3-ketodihy- 
drosphingosine synthesis by binding a subset of SPT com- 
ponents or by disrupting a larger complex. It is also possible 
that the affinity chromatography conditions (0.1% deter- 
gent, 250 mM NaCl) partially dissociate a larger SPT 
complex, although SPT retains optimum activity levels in 
this buffer medium (data not shown). 
Consistent with these observations, the ability of myriocin 
to inhibit SPT is remarkably congruent with the currently 
accepted mechanism of 3-ketodihydrosphingosine biosyn- 
thesis (Figure 14). Isotopic-labeling studies suggest that the 
reaction proceeds by sequential imine formation, a-carbon 
deprotonation, palmitoylation, decarboxylation, protonation 
and imine hydrolysis [3S]. (This mechanism is in contrast 
with an otherwise reasonable alternative of imine formation. 
decarboxylation. palmitoylation and hydrolysis). The obser- 
vation that serine decarboxylation is palmitoyl CoA-depen- 
dent provides additional support for this mechanism and 
indicates the importance of a C3-ketone for substrate decar- 
boxylation [36]. Furthermore, the conservation of CZ-con- 
figuration in serine and 3-ketodihydrosphingosine demands 
that the a-proton/palmitoyl Co,4 and carboxyl group/proton 
substitutions proceed by a combination of stereochemical 
inversion and retention, Within this context, it is likely that 
the first transformation occurs with inversion of configura- 
tion and the second with retention because this sequence 
would require the least molecular motion in the enzyme- 
substrate complex. This mechanistic course is also more 
consistent with the structure of myriocin; the natural 
product stereochemically matches the putative reaction 
intermediate preceding decarboxylation (see Figure 14), 
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Serine palmitoyltransferase activity and its molecular inhibition. (a) The currently accepted mechanism for 3-ketodihydrosphingosine biosynthesis. 
(b) Known SPT inhibitors. 
and the lack of a C3-keto group in myriocin provides a plau- both cellular processes [38,39]. The addition of sphingo- 
sible basis for its potent inhibitory activity. The absence of sine and sphingosine l-phosphate to mammalian fibrob- 
this group should prevent the enzyme from decarboxylating lasts can stimulate DNA synthesis and cell proliferation 
the inhibitor. Other known SPT blockers such as lipoxam- [40,41], and the carcinogenic dihydrosphingosine N-acyl- 
ycin, the sphingofungins and the viridiofungins are struc- cransferase inhibitor fumonisin Bl is believed to stimulate 
turally divergent from this molecular intermediate, and fibroblast mitogenesis by causing intracellular sphingoid 
accordingly they are weaker inhibitors of sphingolipid bio- base accumulation [42]. Cellular targets of such sphingo- 
synthesis than myriocin. It remains to be shown, however, lipids are still enigmatic, but both sphingosine and sphin- 
that myriocin truly abrogates SPT activity by substrate- gosine l-phosphate can modulate intracellular calcium 
competitive binding. Miyake et nl. [9] have reported that mobilization and specific growth-promoting protein kinases 
myriocin inhibits SPT noncompetitively with respect to [15,41,43,44]. These observations suggest that the intra- 
palmitoyl CopI, whereas it has been claimed that the sphin- cellular depletion of certain sphingolipids could impede 
gofungins compete with serine in SPT assays [37]. cell growth or survival. 
In any case, SPT deactivation is biochemically consistent 
with the effect of myriocin on CTLL-2 proliferation and 
apoptosis, because sphingolipids are known modulators of 
It is important to recognize, however, that sphingolipids 
have multiple effects, many of which may be cell lineage- 
dependent. In addition to their mitogenic influence on 
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Swiss 3T3 fibroblasts, sphingosine and sphingosine l-phos- 
phate can induce apoptosis in several cetl lines [4547] and 
the SPT inhibitor P-fluoroalanine has no effect on fibroblast 
proliferation [42]. Moreover, fumonisin Bl-induced accu- 
mulation of sphingobases activates apoptotic pathways in 
colon-derived HT29 cells [48]. Interpretation of these 
seemingly conflicting observations is further complicated 
by the dynamic nature of sphingolipid homeostasis, main- 
tained by the rapid metabolic conversion of exogenous 
sphingolipids by intracellular enzymes. What remains clear 
is that cell survival and proliferation are intimately con- 
nected to specific sphingolipid compositions and concentra- 
tions. The specific outcome of sphingolipid depletion or 
accumulation depends on the cell type and the influence of 
exogenous factors. Because myriocin has no effect on the 
proliferation of several tumor cell lines of diverse origin 
[3,7], it is conceivable that myriocin specifically promotes 
programmed cell death in CTLL-Z-like cells, thereby 
suppressing the immune response against transplanted 
cells and tissue grafts. h’akamura et al. [7] have suggested 
that myriocin sensitivity is limited to CD4-negative and 
CD%positive cytotoxic T cell lineages, although the myri- 
ocin-induced apoptosis of cerebellar Purkinje neurons has 
recently been demonstrated [49]. 
Whether SPT deactivation is the primary mechanism for 
myriocin-mediated immunosuppression is a more difficult 
question to answer, due to the multifaceted nature of the 
mammalian immune system. The inability of FTY720 
and other myriocin-derived immunosuppressants to inhibit 
sphingolipid biosynthesis implies either a fortuitous diver- 
gence in physiological mechanism or the existence of 
another biological target for myriocin. The latter scenario 
would not be unprecedented because sphingoid bases often 
have multiple cellular effects and presumably interact 
with several proteins. Sphingosine l-phosphate has recently 
emerged as the prototype for such multifunctional sphin- 
golipids. At the intracellular level, this sphingosine metabo- 
lite can induce mitogenesis and suppress apoptosis [38], 
but it also binds cell-surface receptors such as endothelial 
differentiation gene-l (EDG-1) to induce cadherin upregu- 
lation and cell-cell aggregation [29]. These diverse cellular 
phenoqpes are mechanistically distinct, demonstrating the 
presence of at least two protein receptors for this novel 
sphingolipid [17]. FTY720 itself appears to have two dis- 
crete effects; the immunosuppressive agent can specifically 
induce the apoptosis of rat spleen cells and human periph- 
eral blood cells, but at lower concentrations it accelerates 
lymphocyte homing and decreases T-cell infiltration of 
tissue allografts [50-521. 
It is even possible that a myriocin (or FTY720) metabolite is 
the primary mediator of immunosuppressive activity. Some 
of the sphingolipid biosynthetic enzymes are known to have 
relatively broad substrate specificities and can act upon 
numerous exogenous sphingoid bases. Dihydrosphingosine 
:V-acyltransferase can condense all four sphinganine and 
sphingosine stereoisomers with a variety of fatty acyl-CoAs 
[53,54],and several sphingoid bases, including all dihydro- 
sphingosine stereoisomers, are phosphorylated in ciao by 
one or more kinases [53,5S-571. Because the degradation of 
sphingosine-like molecules by sphingosine l-phosphate 
lyase appears to bc limited to n-erythrosphingoid bases of 
various chain lengths and types [53,55], these unconven- 
tional metabolites might accumulate in cells and induce 
abnormal phenotypes. In agreement with these observa- 
tions, the enzymatic conversion of exogenous sphingosine- 
like molecules into biologically active metabolites is prece- 
dented for both acylation and phosphorylation processes 
[57,5X]. Given the related structures of myriocin and 
FTY720, these sphingosine-like compounds might undergo 
similar chemical transformations in mammalian cells, pos- 
sibly generating additional modulatory ligands for essen- 
tial cellular proteins. 
Exploring these possibilities will be a daunting task, requir- 
ing the isolation of small molecules and their protein recep- 
tors from several tissues or cell types. The molecular 
studies of myriocin and its derivatives described here 
therefore represent an initial step forward in the systematic 
elucidation of their physiological targets. The chemical 
synthesis of a myriocin-containing affinity matrix has led 
co the biochemical isolation of LCBl and LCBZ from 
CTLL-2 cells, corroborating previous observations that 
myriocin potently inhibits SPT activity and providing 
strong experimental evidence that LCBl and LCB2 are 
fundamental components of this biosynthetic enzyme. 
This molecular reagent and others described above might 
therefore facilitate the discovery of additional myriocin- 
sensitive proteins, which could be specifically expressed in 
other tissues or cell lines. As demonstrated by the success- 
ful identification of LCBl and LCB2 as myriocin-binding 
proteins, these chemistry-based strategies can convey a 
molecular clarity to biological processes, thereby comple- 
menting and supporting traditional genetic approaches. 
Alternatively, CD&A and oligonucleotide microarray tech- 
nologies, which allow the rapid profiling of cellular mRNA 
transcript levels, could facilitate the mechanistic deconvolu- 
tion of myriocin’s biological activities. The observed sensi- 
tivity of S. renzisiau to myriocin and our comprehensive 
knowledge of the yeast genome sets the stage for several 
initial experiments. For example, the effects of myriocin 
and other SPT inhibitors on S. cerxzisiae mRNA transcripts 
could be evaluated in order to determine whether myriocin 
targets yeast proteins that are unrelated to SPT activity. 
Similar assessments could be obtained by comparing the 
transcript profiles of yeast mutants lacking LCBl and/or 
I,CB2 genes to those of myriocin-treated wild-type strains. 
Microarray technologies would also permit the molecular 
dissection of SPT-related phenotypes that result from 
myriocin treatment. Individual contributions of sphingolipid 
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metabolites to cellular homeostasis could be studied by 
analyzing yeast mRNA transcript profiles induced by simul- 
taneous exposure to myriocin and specific sphingolipids. 
These investigations could ultimately be extended to 
mammalian cell lines, promoting our understanding of 
myriocin-induced perturbations in multicellular systems. 
Thus, the combination of small-molecule-based approaches 
with cDNA/oligonucleotide microarray technologies might 
constitute a general strategy for the mechanistic evaluation 
of biologically active compounds. Such investigations are 
now underway (J, Hardwick, J. Tong, J.K.C. and S.L.S., 
unpublished observations). 
Significance 
The natural product myriocin induces apoptosis of a 
murine cytotoxic T lymphocyte cell line (CTLL2) and 
inhibits a serine pabnitoyltransferase (WI’) activity 
thought to initiate sphingolipid biosynthesis. Using syn- 
thetic myriocin derivatives and affinity chromatography, 
two specific myriocin-binding proteins were isolated from 
CTLL-2 cell lysates. This study provides the first bio- 
chemical evidence that LCBl and LCB2, mammalian 
homologs of two yeast proteins that have been linked to 
sphingolipid biosynthesis, are integral components of 
SFT, a sphingolipid biosynthesis enzyme that has eluded 
purification since its discovery three decades ago. Our 
results also demonstrate that myriocin acts directly upon 
these protein subunits, thereby inhibiting SPT activity. 
These results verify the utility of sphingolipid-derived 
reagents to elucidate the molecular machinery of sphingo- 
lipid homeostasis. 
Materials and methods 
AAyriocin isolation from Mycelia sterilia 
Mycelia sfen/;a was obtained from the American Type Culture Collection 
(ATCC; Rockville, MD) as an agar-slant culture, and all fermentations 
were performed using autoclaved fermentation media (3% glucose, 
0.5% Difco yeast extract, 0.03% K,HPO,, 0.034/o KH,PO,, O.O5O/o 
MgSO,) and a 37°C shaker incubator (250 rpm). The ATCC agar slant 
was used to innoculate 3 ml of media, and the fungal culture was main- 
tained for 2 days. The 3 ml culture was then added to 100 ml of media, 
fermented for another 2 days, and then expanded to a final media 
volume of 1.1 I. After this 1.1 I culture was incubated for 15 days, the 
mycelial cake was isolated by filtration, washed with water (2 x 75 ml), 
and extracted with methanol (4 x 75 ml). The methanol extract was sub- 
sequently concentrated in vacua, diluted with an equal volume of water, 
and applied to a 100 ml column of Amberlite XAD-16 (prewashed with 
five volumes of methanol and five volumes of water; Sigma, St. Louis, 
MO). The hydrophobic matrix was washed with water (5 x 100 ml), 
acetone:water:NH,OH (1:4:0.02; 2 x 100 ml), and methanokwater (1:l; 
2 x 100 ml). Myriocin was finally eluted from the column in methanol: 
water (4:l ; 50 x 25 ml fractions). Myriocin-containing fractions were 
pooled and solvent was removed in vacua to yield 100-200 mg of 
crude myriocin (1; at least 90% purity). This crude preparation was used 
directly in the syntheses of myriocin derivatives or recrystallized from 
methanol to provide pure myriocin for biological studies. 
Evaluation of myriocin derivatives in CTLL-2 proliferation assay 
CTLL-2 cells were grown in cell culture media (RPM1 1640; 10% fetal 
bovine serum, 20 mM HEPES, pH 7.4, 2 mM glutamine, 1 mM sodium 
pyruvate, 50 pM 8-mercaptoethanol, 100 U/ml penicillin G, 100 yg/ml 
streptomycin sulfate, 20 U/ml IL-2) in a 5% CO, and 37’C incubator. 
Myriocin and its derivatives were maintained as 1 mM, 100 uM, 10 pM 
and 1 pM stocks in methanol and stored at -20°C. Using these reagents, 
a series of 0.5 ml cultures were established in a 12-well cell culture dish, 
each containing 25,000 CTLL-2 cells, 1% methanol, and the appropriate 
myriocin-derived compound at concentrations ranging from 2.5 nM to 
5pM. A well containing only CTLL-2 cells and 1% methanol was also 
included as a control. The cell cultures were maintained for 3 days and 
then cell populations in each well were counted with either a Levy hemo- 
cytometer (Hausser Scientific) or a Coulter 21 cell counter (particle size 
range 5 10 microns; Coulter Electronics). 
Subcellular fractionation of CTLL-2 cells 
CTLL-2 cells (1 I culture) were grown to a density of approximately 
500,000 cells/ml and collected by centrifugation at 200 g for 5 min. The 
cells were washed once with RPM1 1640 media (40 ml), pelleted again 
by centrifugation, and resuspended in lysis buffer (50 mM sodium phos- 
phate, pH 7.4, 20% glycerol, 150 mM NaCI, 2 mM EDTA, 2 mM EGTA, 
25 mM NaF, 25 mM P-glycerophosphate, 2 mM DlT, 1 FM NaaVO,, 
1 mM Pefabloc SC (Boehringer Mannheim), 1 ug/ml leupeptin, 1 pg/ml 
pepstatin A) to a densrty of 3.2 x lo7 cells/ml. All subsequent steps were 
performed at 4°C. The CTLL-2 cells were first lysed by sonication using a 
Fisher Scientific Model 550 Sonic dismembrator equipped with a 0.125 
in microtip (12 cycles; 10 s sonicationll min pause). This lysate was cen- 
trifuged at 15,000 g for 20 min to yield a pellet, which was subsequently 
resuspended in lysis buffer (15.6 ml) by sonication (3 cycles; 10 s soni- 
cation/l min pause). The 15,OOOg supernatant was recentrifuged at 
100,000 g for 1 h to provide the cytosolic supernatant and the microso- 
mal pellet, which was resuspended in lysis buffer (15.6 ml) by sonication 
(3 x 10 s sonication/l min pause bursts). All three subcellular fractions 
were flash frozen as 1 ml aliquots and stored at -78°C. Further fractiona- 
tion of the microsomal lysate was typically performed immediately prior to 
use. The lysate was rapidly thawed and then treated with IGEPAL CA 
630 (final concentration= 0.1%) for 1 h. The detergent-solubilized mixture 
was centrifuged again at 100,000 g for 1 h, affording a membranous 
pellet and a supernatant containing membrane-dissociated proteins. This 
second 100,000 g pellet was resuspended in lysis buffer (volume equal 
to the original microsomal lysate volume) by sonication (3 cycles; 10 s 
sonication/l min pause). 
SPT assay and evaluation of myriocin derivatives 
SPT activity in CTLL-2 subcellular fractions was assessed by mixing 
lysate (40 pl) with reaction buffer (50 pl: 100 mM HEPES, pH 8.3, 
5 mM DTT, 2.5 mM EDTA, 50 uM PLP, 150 PM palmitoyl CoA) and 
radioactive serine (10 ul; 100 mM stock of HOCT,CH(NH,)COOH 
from DuPont NEN diluted with nonradioactive serine to a final specific 
activity of 45,000 dpmlnmol). Each 100 ul reaction was incubated at 
35’C for 30 min and then quenched with 0.5 N NH,OH (1 ml). Organic- 
soluble radioactive products were isolated by adding 25 ug of dihy- 
drosphingosine or sphingosine (1 mg/ml in EtOH) and 0.75 ml of 
chloroform:methanol (1:2) to the reaction mixture. The biphasic mixture 
was vortexed vigorously and centrifuged (16,000 g for 2 min), and the 
resultant aqueous layer was discarded. The organic layer was subse- 
quently washed with water (2 x 1 ml) by sequential vortexing, centrifu- 
gation, and aqueous layer removal, and a 100 ul aliquot of the organic 
layer was mixed with Ecoscint A (3 ml; National Diagnostics) for analy- 
sis by a Beckman LS 6500 scintillation counter. The effect of myriocin 
or its derivatives on SPT activity was determined by using CTLL-2 
microsomal lysates (without detergent solubilization) and adding 1 ul of 
either methanol or serial dilutions of the appropriate compound dis- 
solved in methanol (100 PM, 10 PM, 1 PM, 0.1 uM or 0.01 uM stocks). 
Synthesis and evaluation of myriocin-affinity matrices 
To prepare the myriocin-affinity matrices, Affigel 102 (5 ml, 81.4 umol of 
amine; BioRad) was first washed with DMF (5 x 5 ml) and resuspended 
in a solution of DMF (2.5 ml) containing succinimidyl 4-(N-maleimido- 
methyl)cyclohexane-1 -carboxylate (SMCC, Pierce; 40.8 mg, 122 pmol) 
and DIPEA (21.5~1, 122 umol) using a fritted reaction vessel (PD-10 
columns, Pharmacia). This suspension was constantly mixed using a 
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rotating tube shaker for 3 h at room temperature and then drained. The 
resultant resin derivative was sequentially washed with DMF (5 x 5 ml), 
isopropanol (5 x 5 ml), and degassed PBS (pH 7.4)lmethanol (1:l; 
5 x 5 ml). The SMCC-functionalized Affigel (30) was then resuspended 
in degassed PBS (pH 7.4)/methanol (total resin and solvent volume= 
5 ml). No free amine remained in the beads, as determined by ninhydrin 
tests. This procedure generates a maleimide-functionalized agarose 
matrix, which can then be reacted with either N-linker myriocin thiol 29, 
or Cl-linker myriocin thiol. 
A typical matrix synthesis is as follows. N-linker myriocin 29 (3.71 mg, 
5.82 pmol) and triscarboxyethylphosphine (TCEP; 3.32 mg, 11.6 umol) 
were dissolved in degassed methanol:water (4:l; 250 pl) and stirred for 
5 min at room temperature. The SMCC-Affigel suspension described 
above (3.57 ml, 58.2 pmoles) was then added to the myriocin/TCEP 
solution, and the reaction was incubated on a rotating tube shaker for 
18 h at room temperature. Afterwards, an aliquot of the reaction super- 
natant (15 pl, containing no agarose beads) was analyzed by reverse- 
phase HPLC (LDC Analytical gradient system; YMC C-18 column, 
4.6 mm x 15 cm; linear gradient from 200/, to 800/o acetonitrile in water 
containing 0.1% TFA in 25 min) to confirm the complete depletion of 29, 
implying quantitative ligand conjugation. Conjugation of myriocin to the 
agarose was also corroborated by positive ninhydrin tests. The remain- 
ing maleimides were quenched by adding @mercaptoethanol (20.4 ul, 
0.291 mmol) to the reaction mixture and incubating the suspension on a 
rotating tube shaker for 6 h at room temperature. The N-linker myriocin- 
functionalized Affigel (31) was then washed with water (5 x5 ml), 
methanol (5 x 5 ml), and isopropanol (5 x 5 ml) and finally resuspended 
in isopropanol (total resin and solvent volume = 7.14 ml). Affrgel matrices 
containing Cl-linker myriocin (32) were synthesized from 30 and Cl- 
linker myriocin thiol using identical procedures, and the Affigel control 
matrix (33) was prepared by reacting the 30 with P-mercaptoethanol 
(5 equiv) for 24 h at room temperature. Similar methods were also uti- 
lized to conjugate myriocin derivatives and P-mercaptoethanol to ethyl- 
aminediamine-functionalized polydimethylacrylamide (PDMA) beads 
(Polymer Labs). All synthesized matrices were stored at -20°C. 
To evaluate the ability of functionalized Affigel matrices 31, 32 and 33 
to sequester cellular proteins, each resin (10 ul of isopropanol suspen- 
sion) was washed with water (1 ml) and incubated with CTLL-2 micro- 
somal lysate (200 ul; see above) containing 0.01% IGEPAL CA 630 
detergent in a 1.5 ml Eppendorf tube. The mixtures were incubated on 
a rotating tube shaker for 1 h at 4°C and then quickly centrifuged to 
pellet the matrices. Supernatants were subsequently analyzed for SPT 
activity using the procedures outlined above. Related protocols were 
followed for the evaluation of myriocin- and P-mercaptoethanol-func- 
tionalized PDMA resins. 
Identification of ~51 and ~55 by affinity chromatography 
In a typical analytical-scale operation, fractionated CTLL-2 lysate (4 m) 
was treated with IGEPAL CA 630 (final concentration =O.l%) and NaCl 
(final concentration = 250 mM) and then mixed with affinity chromatogra- 
phy buffer (16 ml: 50 mM sodium phosphate, pH 7.4; 20% glycerol; 
250 mM NaCI, 0.1% IGEPAL CA 630, 2 mM EDTA, 2 mM EGTA, 
25 mM NaF, 25 mM P-glycerophosphate, 2 mM OTT, 1 uM NasVO,, 
1 mM Pefabloc SC (Boehringer Mannheim), 1 ug/ml leupeptin, 1 pglml 
pepstatin A). The resultant mixture was split into two equal portions 
(2 x IO ml), and all subsequent procedures were performed at 4°C. One 
portion was treated with methanol (20 ul), and the other was treated with 
myriocin (20 ul of a 2.00 mM solution in methanol). After both portions 
were equilibrated for 10 min, each was mixed with N-linker myriocin affin- 
ity matrix (31; 100 ul of isopropanol suspension, drained and washed 
with water (2 x 1 ml) and incubated on a rotating tube shaker for 2 h at 
4°C. The two suspensions were then centrifuged at 2000 g for 5 min to 
pellet the matrices, and the beads were transferred separately to two 
2.0ml Eppendorf tubes, Using these tubes, each matrix was washed 
with the affinity chromatography buffer (3 x 1 ml; plus 0.2% methanol or 
2 uM myriocin, depending on the matrix) and 50 mM sodium phosphate 
buffer (pH 7.4; 2 x 1 ml) by sequential vortexing, centrifugation, and 
buffer removal. Matrix-associated proteins were then recovered by boiling 
the beads with 2x SDS-PAGE loading buffer (30pllaliquot: 1OOmM 
Tris-HCI, pH 6.8; 20% glycerol; 4% SDS; 5% P-mercaptoethanol; 0.2% 
bromophenol blue) for 5 min. The eluted proteins were separated using 
standard SDS-PAGE protocols on a 7.5% acrylamide gel and visualized 
by conventional silver staining procedures. Specific binding proteins ~51 
and ~55 were identified by comparisons between the methanol- and 
myriocin-treated lysates. 
Isolation of specific myriocin-binding proteins for sequencing analysis 
required a 20-fold increase in scale, using procedures similar to those 
described above. Matrix proteins were recovered as before by boiling 
the beads with SDS-containing buffer (50 mM Tris-HCI, pH 6.8, 0.5% 
SDS, 5% j3-mercaptoethanol) for 5 min, and the resin eluates obtained 
from the methanol-treated lysates were pooled. Both protein solutions 
were passed through 0.45 urn filters (Millipore Ultrafree) to remove any 
particulates. Concentration of the methanol-treated eluate was then 
achieved by first diluting the pooled solution fivefold with buffer (50 mM 
Tris-HCI (pH 6.8) and 5% j3-mercaptoethanol) and cooling it on ice for 
30 min. These conditions bring the SDS levels below its critical micelle 
concentration, allowing the solution volume to be reduced by ultrafiltra- 
tion (Millipore Ultrafree 4, 10 kD molecular weight cut-off) without exces- 
sive SDS concentration. Using this procedure, the methanol-treated 
eluate were reduced to a volume of 30 j.tI and then boiled with 5x 
SDS-PAGE loading buffer (7.5 ul: 60 mM Tris-HCI pH 6.8, 250/, glyc- 
erol, 2% SDS, 5% P-mercaptoethanol, 0.1% bromophenol blue). The 
matrix-eluted proteins were separated using standard SDS-PAGE pro- 
tocols on a 7.5% acrylamide gel and were visualized using a modified 
silver staining protocol designed for mass spectrometry samples. 
Bands corresponding to p51 and p55 were identified using a control 
sample obtained from the myriocin-treated lysates, and excised from 
the acrylamide gel. The gel fragments were subsequently transferred to 
separate Eppendorf tubes, washed with acetonitrile:water (1 :l; 3 x 1 ml, 
1 min each wash), and stored at -20°C until trypsinization and MS-based 
sequence analysis was performed. 
PCR cloning of LCB7 and LCBP cDNAs 
LCB7 cDNA. The LCBl cDNA flanked by C/al and EcoRl restriction 
sites and a 5’ Kozak sequence was PCR-amplified from a mouse adult 
BALBlc male kidney cDNA library (Clontech QUICK-Clone) using the 
following primers: 5’CC ATC GAT ACC ATG GCG ACA GTG GCG 
GAG CAG-3’ and 5’CG GAA TTC CTA CAA CAG CAC AGC CTG 
GGC-3’. The PCR product was then subcloned into the CS2- vector 
through C/al and EcoRl restriction sites, and sequence integrity was 
confirmed by automated chain-termination methods. 
LCBP CD/VA. The CS2-LCB2 construct was obtained and character- 
ized by analogous procedures using the following primers: 5’CC ATC 
GAT ACC ATG CGG CCG GAG CCC GGA GGCS’ and 5’.CG GAA 
TTC TCA GTC T-TC TGT CTC TTC ATA-3’. 
In vitro transcription/translation of LCf37 and LCBP 
The LCBl and LCB2 proteins were obtained by in vitro transcription 
and translation of the CS2-LCBl and CS2-LCB2 plasmid constructs, 
using an SP6 polymerase-coupled rabbit reticulocyte lysate system 
(Promega) as indicated by Promega protocols. Both nonradioactive 
and radioactive translation products were generated using cold or 
[ssS]-labeled methionine (Amersham) in the presence of RNAsin ribo- 
nuclease inhibitor (Promega). To compare the p51 and LCBl proteins, 
samples of affinity matrix-associated proteins and [35S]-labeled LCBl 
were analyzed by SDS-PAGE (10% acrylamide gel). The separated pro- 
teins were visualized by silver staining and dehydrated onto Whatman 
filter paper for autoradiography. The p55 and LCB2 proteins were simi- 
larly resolved by SDS-PAGE (7.5% acrylamide gel) and visualized by 
western blotting using the u-LCB2 antibody (see below). 
Mass spectrometry-based sequencing of p5 1 and ~55 
Silver stained p51 and p55 samples were subjected to in gel reduc- 
tion, carboxyamidomethylation and tryptic digestion (Promega). Multiple 
peptide sequences were determined in a single run by microcapillary 
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reverse-phase chromatography directly coupled to a Finnigan LCQ 
quadrupole ion trap mass spectrometer equipped with a custom nano- 
electrospray source. The column was packed in-house with 5 cm of Cl 8 
support into a New Objective one-piece 75 pm I.D. column terminating in 
a 8.5 urn tip. Flow rate was 190 nllmin. The ion trap was programmed to 
acquire successive sets of three scan modes consisting of: full scan MS 
over alternating ranges of 395-800 m/z or 800-l 300 m/z, followed by 
two data-dependent scans on the most abundant ion in those full scans. 
These data dependent scans allowed the automatic acquisition of a high 
resolution (zoom) scan to determine charge state and exact mass, and 
tandem mass spectroscopy (MS/MS) spectra for peptide sequence 
information. MS/MS spectra were acquired with a relative collision 
energy of 30%, an isolation width of 2.5 Da and with previously observed 
ions dynamically excluded from MS/MS analysis. Interpretation of the 
resulting MS/MS spectra of the peptides was facilitated by programs 
developed by the Harvard Microchemsitry Facility and by database corre- 
lation with the algorithm Sequest [33,34]. 
Production of a-LCB7 and (w-LCB2 polyclonal antibodies 
a-LCB7 antibody. The peptide AC-CGSTGSREKDVKLLQAI-NH, 
(CG and LCBl residues 401-415; 2.19 mg, 1 pmole) was conjugated 
to maleimide-functionalized keyhole limpet hemocyanin (KLH; 2 mg, 
0.7 umole maleimide) as described in the lmject protocols by its sup- 
plier (Pierce). Purification by size exclusion chromatography yielded 3 ml 
of KLH-peptide conjugate, which was flash frozen and stored at -20°C 
until rabbit immunization. Bleeds were obtained at appropriate intervals, 
allowed to clot on ice, and then centrifuged at 3000 g for 10 min. The 
serum was subsequently removed, flash frozen, and stored at -78°C. 
a-LC62 antibody. Antisera for the LCB2 protein was obtained through 
analogous methods using the peptide Ac-CGKYSRHRLVPLLDRPF- 
NH, (CG and LCB2 residues 536-550). 
Characterization of p5 1 and p55 by western blotting 
Antisera and preimmune sera from rabbits were used for western blot- 
ting analyses as described in the ECL protocols by its supplier (Amer- 
sham). Matrix-associated proteins were separated by SDS-PAGE 
(7.5% acrylamide gels) and transferred to PDVF membranes (Immo- 
bilon P, Millipore). All incubations and washes were conducted with 
either PBS-T buffer (PBS, pH 7.4; 0.05% Tween-PO) or TBS-T buffer 
(20 mM Tris-HCI pH 7.4, 150 mM NaCI, 0.1% Tween-PO). Blocking of 
non-specific sites was accomplished by incubating the PDVF mem- 
brane in 10% non-fat dry milk in either buffer system. The o-LCBl sera 
were used in a 1:20 dilution in TBS-T containing 1% non-fat dry milk, 
whereas the a-LCB2 sera were used in a 1:250 dilution in PBS-T. The 
corresponding preimmune sera controls were analyzed using identical 
conditions. Donkey-derived a-rabbit lg conjugated to horseradish per- 
oxidase (Amersham) was used as a 1 :lOOOO dilution with the appropri- 
ate buffer, and detection of the secondary antibody was accomplished 
according to the ECL protocols (Amersham). 
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